CLMBEarnings•globenewswire•
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Sentiment:Neutral (40)
Summary
Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire